Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression

Breast Cancer Research

Volumn 14, Issue 6, 2012, Pages

  Rezaei, Maryam ^a,c   Friedrich, Katrin ^a   Wielockx, Ben ^a   Kuzmanov, Aleksandar ^a,d   Kettelhake, Antje ^a   Labelle, Myriam ^b   Schnittler, Hans ^c   Baretton, Gustavo ^a   Breier, Georg ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN; CADHERIN; GEMIN2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NERVE PROTEIN; RNA BINDING PROTEIN; SMALL INTERFERING RNA; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CARCINOMA CELL; CELL MEMBRANE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST; BREAST TUMOR; CANCER TRANSPLANTATION; DISEASE COURSE; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; BETA CATENIN; BREAST; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; VIMENTIN;

EID: 84870425389     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3367     Document Type: Article

References (48)

1. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann NY Acad Sci 2004, 1014:155-163. 10.1196/annals.1294.016, 15153430.
2. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999, 24:73-76. 10.1016/S0968-0004(98)01343-7, 10098402.
3. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci 2008, 121:727-735. 10.1242/jcs.000455, 18322269.
4. Takeichi M. Self-organization of animal tissues: cadherin-mediated processes. Dev Cell 2011, 21:24-26. 10.1016/j.devcel.2011.06.002, 21763603.
5. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 2009, 16:209-21. 10.1016/j.devcel.2009.01.004, 19217423.
6. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117-134. 10.1007/s10911-010-9178-9, 2886089, 20490631.
7. Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res 2008, 68:1388-1397. 10.1158/0008-5472.CAN-07-2706, 18316602.
8. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999, 147:631-644. 10.1083/jcb.147.3.631, 2151177, 10545506.
9. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000, 148:779-790. 10.1083/jcb.148.4.779, 2169367, 10684258.
10. Islam S, Carey TE, Wolf GT, Wheelock MJ, Johnson KR. Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J Cell Biol 1996, 135:1643-1654. 10.1083/jcb.135.6.1643, 2133960, 8978829.
11. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001, 98:8018-8023. 10.1073/pnas.131209798, 35460, 11416160.
12. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006, 5:228-33. 10.4161/cbt.5.2.2510, 16481735.
13. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 2005, 65:11520-11528. 10.1158/0008-5472.CAN-05-2468, 16357161.
14. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995, 154:8-20.
15. Klymkowsky MW. beta-catenin and its regulatory network. Hum Pathol 2005, 36:225-227. 10.1016/j.humpath.2005.02.002, 15791565.
16. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119:1429-1437. 10.1172/JCI36183, 2689132, 19487819.
17. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213:374-383. 10.1002/jcp.21223, 17680632.
18. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010, 101:293-299. 10.1111/j.1349-7006.2009.01419.x, 19961486.
19. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
20. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17:548-558. 10.1016/j.ceb.2005.08.001, 16098727.
21. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001, 98:10356-10361. 10.1073/pnas.171610498, 56965, 11526241.
22. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006, 66:11271-11278. 10.1158/0008-5472.CAN-06-2044, 17145872.
23. Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008, 25:643-655. 10.1007/s10585-008-9171-5, 2836537, 18398687.
24. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010, 9:179. 10.1186/1476-4598-9-179, 2907333, 20609236.
25. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996, 10:2462-2477. 10.1101/gad.10.19.2462, 8843198.
26. Breier G, Blum S, Peli J, Groot M, Wild C, Risau W, Reichmann E. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 2002, 97:142-148. 10.1002/ijc.1599, 11774256.
27. Kuzmanov A, Wielockx B, Rezaei M, Kettelhake A, Breier G. Overexpression of factor inhibiting HIF-1 enhances tumor growth through improved blood vessel maturation. Int J Cancer 2012, 131:E603-613. 10.1002/ijc.27360, 22095574.
28. Jaggi M, Wheelock MJ, Johnson KR. Differential displacement of classical cadherins by VE-cadherin. Cell Commun Adhes 2002, 9:103-115. 10.1080/15419060214150, 12487411.
29. Navarro P, Ruco L, Dejana E. Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J Cell Biol 1998, 140:1475-1484. 10.1083/jcb.140.6.1475, 2132661, 9508779.
30. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981. 10.1083/jcb.200601018, 2063755, 16567498.
31. Li H, Pamukcu R, Thompson WJ. beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 2002, 1:621-625.
32. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003, 129:199-221.
33. Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, Nohno T. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer 2007, 6:62. 10.1186/1476-4598-6-62, 2140063, 17922924.
34. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 1999, 112:1237-1245.
35. Kawashima M, Kawakita T, Higa K, Satake Y, Omoto M, Tsubota K, Shimmura S, Shimazaki J. Subepithelial corneal fibrosis partially due to epithelial-mesenchymal transition of ocular surface epithelium. Mol Vis 16:2727-2732.
36. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 2003, 63:2658-2664.
37. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 2006, 25:4975-4985. 10.1038/sj.onc.1209511, 16568083.
38. Raymond WA, Leong AS. Vimentin-a new prognostic parameter in breast carcinoma?. J Pathol 1989, 158:107-114. 10.1002/path.1711580205, 2547048.
39. Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther 2009, 8:499-508. 10.1158/1535-7163.MCT-08-0544, 2703491, 19276168.
40. Luo Y, Radice GL. N-cadherin acts upstream of VE-cadherin in controlling vascular morphogenesis. J Cell Biol 2005, 169:29-34. 10.1083/jcb.200411127, 2171890, 15809310.
41. Tiraby C, Hazen BC, Gantner ML, Kralli A. Estrogen-related receptor gamma promotes mesenchymal-to-epithelial transition and suppresses breast tumor growth. Cancer Res 2011, 71:2518-2528. 10.1158/0008-5472.CAN-10-1315, 3070807, 21339306.
42. Hong KO, Kim JH, Hong JS, Yoon HJ, Lee JI, Hong SP, Hong SD. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J Exp Clin Cancer Res 2009, 28:28. 10.1186/1756-9966-28-28, 2651854, 19243631.
43. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995, 55:5195-5199.
44. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2010, 30:1436-1448.
45. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428. 10.1038/nrc2131, 17508028.
46. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001, 3:289-293. 10.1186/bcr309, 138690, 11597316.
47. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, van Eijk R, Eilers PH, van de Water B, Cornelisse CJ, Cleton-Jansen AM. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006, 94:661-671. 2361216, 16495925.
48. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449. 10.1016/j.ccr.2006.09.013, 17097565.